{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:14:47Z","timestamp":1783484087299,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clbc.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:28:30Z","timestamp":1778891310000},"page":"10-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Vincenzo","family":"Di Lauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola C.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccimarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gridelli","family":"Cesare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Massafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clbc.2026.05.004_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"10.1016\/j.clbc.2026.05.004_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1340764","article-title":"Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy","volume":"15","author":"Cao","year":"2024","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.clbc.2026.05.004_bib0003","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2026.05.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111322","article-title":"Mechanisms of endocrine therapy resistance in breast cancer","volume":"532","author":"Rasha","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.clbc.2026.05.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104793","article-title":"The evolving landscape of hormone receptor-positive\/HER2-negative metastatic breast cancer (EVOLVE): an Italian Delphi consensus report","volume":"213","author":"Miglietta","year":"2025","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"3","key":"10.1016\/j.clbc.2026.05.004_bib0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.clbc.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.05.004_bib0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2026.05.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251336623","article-title":"Options after progression on first-line CDK4\/6 inhibitors in advanced breast cancer patients","volume":"17","author":"Jia","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/COC.0000000000001209","article-title":"Inavolisib for HR-positive, HER2-negative advanced breast cancer: clinical trials and patient access implication","volume":"48","author":"Arabshomali","year":"2025","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.05.004_bib0011","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMc2415114","article-title":"Inavolisib therapy in advanced breast cancer","volume":"392","author":"Ibraheem","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clbc.2026.05.004_bib0012","article-title":"FDA approves Inavolisib combo for PIK3CA-mutated, HR+ breast cancer","author":"Zhang","year":"2025","journal-title":"Curr Med Chem."},{"issue":"28","key":"10.1016\/j.clbc.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1200\/JCO-25-00663","volume":"43","author":"Wedam","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/genes11070719","article-title":"PTEN alterations and their role in cancer management: are we making headway on precision medicine?","volume":"11","author":"Fusco","year":"2020","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.clbc.2026.05.004_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030510","article-title":"Molecular insights into the classification of luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors","volume":"20","author":"Lopez","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2026.05.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9258396","article-title":"Signal transduction pathways in breast cancer: the important role of PI3K\/akt\/mTOR","volume":"2020","author":"Ortega","year":"2020","journal-title":"J Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"195","key":"10.1016\/j.clbc.2026.05.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002165","article-title":"Structural basis for activation and inhibition of class I phosphoinositide 3-kinases","volume":"4","author":"Vadas","year":"2011","journal-title":"Sci Signal"},{"issue":"2","key":"10.1016\/j.clbc.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nchembio.293","article-title":"The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors","volume":"6","author":"Berndt","year":"2010","journal-title":"Nat Chem Biol"},{"issue":"5","key":"10.1016\/j.clbc.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molcel.2011.01.026","article-title":"Structure of lipid kinase p110\u03b2\/p85\u03b2 elucidates an unusual SH2-domain-mediated inhibitory mechanism","volume":"41","author":"Zhang","year":"2011","journal-title":"Mol Cell"},{"issue":"5857","key":"10.1016\/j.clbc.2026.05.004_bib0021","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1126\/science.1150799","article-title":"The structure of a human p110alpha\/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations","volume":"318","author":"Huang","year":"2007","journal-title":"Science"},{"issue":"6759","key":"10.1016\/j.clbc.2026.05.004_bib0022","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/46319","article-title":"Structural insights into phosphoinositide 3-kinase catalysis and signalling","volume":"402","author":"Walker","year":"1999","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.clbc.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1002\/j.1460-2075.1996.tb00727.x","article-title":"Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase","volume":"15","author":"Breeze","year":"1996","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.clbc.2026.05.004_bib0024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1006\/jmbi.1996.0190","article-title":"Crystal structure of P13K SH3 domain at 20 angstroms resolution","volume":"257","author":"Liang","year":"1996","journal-title":"J Mol Biol"},{"issue":"25","key":"10.1016\/j.clbc.2026.05.004_bib0025","doi-asserted-by":"crossref","first-page":"14373","DOI":"10.1073\/pnas.93.25.14373","article-title":"Crystal structure of the breakpoint cluster region-homology domain from phosphoinositide 3-kinase p85 alpha subunit","volume":"93","author":"Musacchio","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.clbc.2026.05.004_bib0026","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nsb0496-364","article-title":"Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes","volume":"3","author":"Nolte","year":"1996","journal-title":"Nat Struct Biol"},{"issue":"4","key":"10.1016\/j.clbc.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1006\/jmbi.1999.3111","article-title":"Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate","volume":"292","author":"Hoedemaeker","year":"1999","journal-title":"J Mol Biol"},{"issue":"51","key":"10.1016\/j.clbc.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"15860","DOI":"10.1021\/bi001474d","article-title":"NMR structure of the N-SH2 of the p85 subunit of phosphoinositide 3-kinase complexed to a doubly phosphorylated peptide reveals a second phosphotyrosine binding site","volume":"39","author":"Weber","year":"2000","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.clbc.2026.05.004_bib0029","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/MCB.18.3.1379","article-title":"Regulation of the p85\/p110 phosphatidylinositol 3\u2032-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit","volume":"18","author":"Yu","year":"1998","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.clbc.2026.05.004_bib0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/viru.20932","article-title":"Influenza A viruses and PI3K: are there time, place and manner restrictions?","volume":"3","author":"Ayllon","year":"2012","journal-title":"Virulence"},{"issue":"1","key":"10.1016\/j.clbc.2026.05.004_bib0031","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jbior.2012.09.005","article-title":"Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H\/D exchange (HDX-MS)","volume":"53","author":"Burke","year":"2013","journal-title":"Adv Biol Regul"},{"issue":"38","key":"10.1016\/j.clbc.2026.05.004_bib0032","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1073\/pnas.1205508109","article-title":"Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110\u03b1 (PIK3CA)","volume":"109","author":"Burke","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clbc.2026.05.004_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.644737","article-title":"PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"11","author":"Fusco","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.05.004_bib0034","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2159-8290.CD-21-0072","article-title":"RTK-dependent inducible degradation of mutant PI3K\u03b1 drives GDC-0077 (Inavolisib) efficacy","volume":"12","author":"Song","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.clbc.2026.05.004_bib0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-024-02136-y","article-title":"Inavolisib: first approval","volume":"85","author":"Blai","year":"2025","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.clbc.2026.05.004_bib0036","first-page":"120","article-title":"Inavolisib: a selective inhibitor of mutant PI3K\u03b1 for the treatment of breast cancer","volume":"3","author":"De","year":"2025","journal-title":"Opin Oncol Adv"},{"issue":"Suppl 2","key":"10.1016\/j.clbc.2026.05.004_bib0037","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1053\/j.seminoncol.2011.04.002","article-title":"Novel agents and future directions for refractory breast cancer","volume":"38","author":"Burstein","year":"2011","journal-title":"Semin Oncol"},{"issue":"113","key":"10.1016\/j.clbc.2026.05.004_bib0038","first-page":"65","article-title":"Targeting the cyclin D-cyclin-dependent kinase (CDK) 4\/6-retinoblastoma pathway with selective CDK 4\/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions","volume":"21","author":"Spring","year":"2016","journal-title":"Discov Med"},{"issue":"13","key":"10.1016\/j.clbc.2026.05.004_bib0039","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","article-title":"Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4\/6 inhibitor in various solid tumors","volume":"23","author":"Tripathy","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6331","key":"10.1016\/j.clbc.2026.05.004_bib0040","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aah6893","article-title":"PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D","volume":"355","author":"Toska","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.clbc.2026.05.004_bib0041","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.clbc.2026.05.004_bib0042","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1172\/JCI66764","article-title":"ErbB3 downregulation enhances luminal breast tumor response to antiestrogens","volume":"123","author":"Morrison","year":"2013","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.clbc.2026.05.004_bib0043","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"283","key":"10.1016\/j.clbc.2026.05.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"33","key":"10.1016\/j.clbc.2026.05.004_bib0045","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.24.00110","article-title":"Phase I\/Ib trial of Inavolisib plus Palbociclib and Endocrine therapy for PIK3CA-mutated, hormone receptor-positive, Human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.clbc.2026.05.004_bib0046","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1200\/JCO.2025.43.16_suppl.1003","volume":"43","author":"Turner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.05.004_bib0047","article-title":"FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer","year":"2024","journal-title":"FDA"},{"key":"10.1016\/j.clbc.2026.05.004_bib0048","unstructured":"European Commission approves Roche\u2019s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation. News release. Roche, 2025. Accessed July 23, 2025. https:\/\/www.roche.com\/media\/releases\/med-cor-2025-07-23"},{"issue":"10","key":"10.1016\/j.clbc.2026.05.004_bib0049","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/00498254.2024.2415103","article-title":"Preclinical assessment of the PI3K\u03b1 selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human","volume":"54","author":"Salphati","year":"2024","journal-title":"Xenobiotica"},{"issue":"24","key":"10.1016\/j.clbc.2026.05.004_bib0050","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","article-title":"Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1","volume":"65","author":"Hanan","year":"2022","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.clbc.2026.05.004_bib0051","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2159-8290.CD-21-0072","article-title":"La degradazione inducibile dipendente da RTK del PI3K\u03b1 mutante determina l'efficacia di GDC-0077 (Inavolisib)","volume":"12","author":"Song","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clbc.2026.05.004_bib0052","unstructured":"Genentech Inc. ITOVEBI (inavolisib) tablets, for oral use: US prescribing information. 2024. https:\/\/www.gene.com\/download\/pdf\/itovebi_prescribing.pdf. Accessed 18 Nov 2024."},{"issue":"4","key":"10.1016\/j.clbc.2026.05.004_bib0053","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1124\/dmd.122.001096","article-title":"Absorption, metabolism, and excretion of Taselisib (GDC-0032), a potent \u03b2-sparing PI3K inhibitor in rats, dogs, and humans","volume":"51","author":"Ma","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"S1","key":"10.1016\/j.clbc.2026.05.004_bib0054","first-page":"92","article-title":"A single-arm study to investigate absolute bioavailability & mass balance of inavolisib in healthy volunteers using a stable-labeled isotope & a radio-labeled isotope [abstract no. 082]","volume":"11","author":"Jindal","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clbc.2026.05.004_bib0055","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.24.00110","article-title":"Phase I\/Ib trial of Inavolisib plus Palbociclib and endocrine therapy for PIK3CA-mutated, hormone receptor\u2013Positive, Human epidermal growth factor receptor 2\u2013Negative advanced or metastatic breast cancer","volume":"42","author":"Komal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.05.004_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115397","article-title":"Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): an open-label, multicenter, dose-escalation and dose-expansion phase 1\/1b study","volume":"221","author":"Bedard","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2026.05.004_bib0057","first-page":"508","author":"Hope","year":"2025","journal-title":"ESMO"},{"issue":"Suppl 7","key":"10.1016\/j.clbc.2026.05.004_bib0058","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1016\/j.annonc.2022.07.235","article-title":"A randomized, openlabel, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy \u00b1 the PI3K inhibitor inavolisib in patients (pts) with HER2+\/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa [abstract no. 200TiP]","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.clbc.2026.05.004_bib0059","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2026.05.004_bib0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with Inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clbc.2026.05.004_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105303","article-title":"Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)","volume":"10","author":"Gambardella","year":"2025","journal-title":"ESMO Open"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:28:13Z","timestamp":1783481293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1526820926000777"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.05.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}